{
    "root": "e54d008a-9b47-42fa-a8c1-23dc72527132",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Naproxen",
    "value": "20250314",
    "ingredients": [
        {
            "name": "NAPROXEN",
            "code": "57Y76R9ATQ"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        }
    ],
    "indications": "Naproxen tablets are indicated for:\n                  The relief of the signs and symptoms of:\n                  \n                     rheumatoid arthritis\n                     osteoarthritis\n                     ankylosing spondylitis\n                     Polyarticular Juvenile Idiopathic Arthritis\n                     tendonitis\n                     bursitis\n                     acute gout\n                  \n                  The management of:\n                  \n                     pain\n                     primary dysmenorrhea",
    "contraindications": "Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. ( 2.1 ) R h e u m a toid Arthritis, Osteoarthritis, and Ankylosing Spondylitis Naproxen tablets 250 mg 375 mg 500 mg twice daily twice daily twice daily The dose may be adjusted up or down depending on the clinical response of the patient. In patients who tolerate lower doses well, the dose may be increased to naproxen 1,500 mg/day for up to 6 months. Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets may not allow for the flexible dose titration needed in pediatric patients with polyarticular juvenile idiopathic arthritis. A liquid formulation may be more appropriate. Recommended total daily dose of naproxen is approximately 10 mg/kg given in 2 divided doses. Dosing with naproxen tablets is not appropriate for children weighing less than 50 kilograms. A c u te Gout Recommended starting dose 750 mg of naproxen tablets followed by 250 mg every 8 hours until the attack has subsided.",
    "warningsAndPrecautions": "Naproxen Tablets USP, 250 mg, are supplied as white, round, biconvex tablets, debossed with “IP 188” on obverse and “250” on the reverse. They are available as follows:\n                  Bottles of 100:                                    NDC 53746-188-01\n                  Bottles of 500:                                    NDC 53746-188-05\n                  Bottles of 1000:                                  NDC 53746-188-10\n                  Naproxen Tablets USP, 375 mg, are supplied as white, capsule-shaped, biconvex tablets, debossed with “IP 189” on obverse and “375” on the reverse. They are available as follows:\n                  Bottles of 100:                                   NDC 53746-189-01\n                  Bottles of 500:                                   NDC 53746-189-05\n                  Bottles of 1000:                                 NDC 53746-189-10\n                  Naproxen Tablets USP, 500 mg, are supplied as white, capsule-shaped, biconvex tablets, debossed with “IP 190” on obverse and “500” on the reverse. They are available as follows:\n                  Bottles of 100:                                   NDC 53746-190-01\n                  Bottles of 500:                                   NDC 53746-190-05\n                  Bottles of 1000:                                 NDC 53746-190-10\n                   Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense in well-closed, light-resistant containers as defined in the USP.",
    "adverseReactions": "Naproxen tablets are contraindicated in the following patients:\n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [see Warnings and Precautions (5.7, 5.9)]\n                     \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [see Warnings and Precautions (5.7, 5.8)]\n                     \n                     In the setting of coronary artery bypass graft (CABG) surgery [see Warnings and Precautions (5.1)]"
}